Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
10 févr. 2021 16h05 HE
|
Genmab A/S
Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL,...
ElsaLys Biotech annonce l'acceptation par la FDA du dépôt de sa demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte
23 juil. 2020 08h00 HE
|
Elsalys Biotech
ElsaLys Biotech annonce l'acceptation par la FDA du dépôt de sa demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte...
ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients
23 juil. 2020 08h00 HE
|
Elsalys Biotech
ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients ·The Biologics License...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
06 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
17 juin 2019 06h00 HE
|
VBI Vaccines, Inc.
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...